Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Laura Johnston, MD
- Robert Negrin, M.D.
- Robert Lowsky, MD
- Samuel Strober, MD
- Richard Hoppe
- Ginna G. Laport
- Kenneth Weinberg
- drug : Cyclosporine
- drug : Anti-Thymocyte Globulin
- drug : G-CSF
- drug : Mycophenolate Mofetil
- procedure : non-myeloablative hematopoietic cell transplantation
Phase: Phase 2
Ages Eligible For Study:
- a haploidentical donor is available